What health experts think of the growing Ozempic “microdosing” trend that claims taking very small doses of GLP-1 drugs can still help people lose weight with fewer side effects at a lower cost.

Newly released data shows that the U.S. may have reached peak obesity in 2020 — and the timing unsurprisingly coincides with the rise of Ozempic and other popular weight loss drugs.

It seems as though Ozempic and other weight-loss jabs are everywhere – and the appetite for them shows no signs of slowing down – with the industry accelerating so fast it’s projected to be worth $100 billion within the next decade.

A study suggests that weight loss medications like Ozempic may help reduce the risk of overdose and alcohol intoxication in people with substance use disorders.

Ozempic and similar products cut opioid and alcohol abuse by up to half, according to research that adds to evidence of the hugely popular blockbuster drugs’ broad potential beyond tackling obesity and diabetes.

One of the most prominent medical developments in recent years has been the emergence of a class of drugs called glucagon-like peptide-1 receptor agonists (GLP-1 RAs). The best known of these drugs is Ozempic,

Research from earlier this week is the latest to suggest that semaglutide and other GLP-1 drugs can help treat people's addiction to both opioids and alcohol.

In a huge new statistical analysis, researchers have found more evidence than ever that drugs like Ozempic can help curb alcohol and opioid addiction. Published in the journal Addiction, this new study saw researchers from Loyola University Chicago sift through more than 1.